Please login to the form below

Not currently logged in
Email:
Password:

Flixabi

This page shows the latest Flixabi news and features for those working in and with pharma, biotech and healthcare.

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Meanwhile, as a rider to the licensing deal, Biogen has also taken on exclusive commercial rights to three other Samsung Bioepis TNF inhibitor biosimilars in China – Benepali (etanercept), Flixabi (infliximab) and

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Behavioural Science in Healthcare
Personal health and wellbeing has never been more a part of the public conscious than it is now....
Why aren't doctors using digital therapeutics?
The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these...
Dec PME cover
Creativity in storytelling: why pharma must invest more in creativity
Chris Ross explores the value, the art and the much-rumoured death of creativity...

Infographics